Serotonin 2A receptor antagonists for treatment of schizophrenia

APD125, a Selective Serotonin 5-HT2A Receptor Inverse Agonist, Significantly Improves Sleep Maintenance in Primary Insomnia

(2017) Russell Rosenberg et al.   SLEEP

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

(2011) Bruce J. Kinon et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia

(2010) Hans Rasmussen et al.   ARCHIVES OF GENERAL PSYCHIATRY

Hetero-dimerization of serotonin 5-HT2A and dopamine D2 receptors

(2010) Sylwia Łukasiewicz et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?

(2010) Richard Mailman et al.   CURRENT PHARMACEUTICAL DESIGN

Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms

(2010) Bjørn H. Ebdrup et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Enhanced Function of Prefrontal Serotonin 5-HT2 Receptors in a Rat Model of Psychiatric Vulnerability

(2010) M. Benekareddy et al.   JOURNAL OF NEUROSCIENCE

Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses

(2010) Philipp T. Meyer et al.   NEUROIMAGE

Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine

(2010) Hans Rasmussen et al.   PSYCHOPHARMACOLOGY

Sensorimotor Gating Depends on Polymorphisms of the Serotonin-2A Receptor and Catechol-O-Methyltransferase, but Not on Neuregulin-1 Arg38Gln Genotype: A Replication Study

(2009) Boris B. Quednow et al.   BIOLOGICAL PSYCHIATRY

Imaging the Glutamate System in Humans: Relevance to Drug Discovery for Schizophrenia

(2009) James Stone   CURRENT PHARMACEUTICAL DESIGN

Antagonism of serotonergic 5-HT2A/2Creceptors: mutual improvement of sleep, cognition and mood?

(2009) H.-P. Landolt et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis

(2009) Herbert Y Meltzer et al.   NEUROPSYCHOPHARMACOLOGY

Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms

(2009) Gavin P Reynolds et al.   PHARMACOLOGY & THERAPEUTICS

Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings

(2009) S. Navari et al.   PSYCHOLOGICAL MEDICINE

Combined administration of an mGlu2/3 receptor agonist and a 5-HT2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants

(2009) Jason M. Uslaner et al.   PSYCHOPHARMACOLOGY

Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [18F]Fallypride PET Study

(2008) Gerhard Gründer et al.   AMERICAN JOURNAL OF PSYCHIATRY

Sensorimotor Gating of Schizophrenia Patients Is Influenced by 5-HT2A Receptor Polymorphisms

(2008) Boris B. Quednow et al.   BIOLOGICAL PSYCHIATRY

Pyramidal Neurons in Rat Prefrontal Cortex Projecting to Ventral Tegmental Area and Dorsal Raphe Nucleus Express 5-HT2A Receptors

(2008) P. Vazquez-Borsetti et al.   CEREBRAL CORTEX

Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality

(2008) J. McGrath et al.   EPIDEMIOLOGIC REVIEWS

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

(2008) Atheir Abbas et al.   EXPERT OPINION ON PHARMACOTHERAPY

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

(2008) Stefan Leucht et al.   LANCET

Identification of a serotonin/glutamate receptor complex implicated in psychosis

(2008) Javier González-Maeso et al.   NATURE

Cortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients

(2008) David Erritzoe et al.   NEUROPSYCHOPHARMACOLOGY

Building a better antipsychotic: Receptor targets for the treatment of multiple symptom dimensions of schizophrenia

(2008) Dennis H. Kim et al.   Neurotherapeutics

Gene-Environment Interactions in Schizophrenia: Review of Epidemiological Findings and Future Directions

(2008) J. van Os et al.   SCHIZOPHRENIA BULLETIN

Serotonin research: contributions to understanding psychoses

(2008) M GEYER et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined

(2007) Lars H. Pinborg et al.   NEUROIMAGE